Q3 2017 EPS Estimates for Five Prime Therapeutics, Inc. Cut by Analyst (FPRX)

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) – Jefferies Group reduced their Q3 2017 earnings per share (EPS) estimates for Five Prime Therapeutics in a report released on Wednesday. Jefferies Group analyst E. Yang now anticipates that the biotechnology company will post earnings of ($1.50) per share for the quarter, down from their previous forecast of ($1.22). Jefferies Group currently has a “Buy” rating and a $52.00 price target on the stock. Jefferies Group also issued estimates for Five Prime Therapeutics’ Q4 2017 earnings at ($1.54) EPS, FY2017 earnings at ($5.78) EPS, FY2018 earnings at ($6.41) EPS, FY2019 earnings at ($5.46) EPS, FY2020 earnings at ($4.66) EPS and FY2021 earnings at ($2.24) EPS.

Several other research firms also recently weighed in on FPRX. Zacks Investment Research upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a report on Wednesday, April 26th. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, BidaskClub downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $60.80.

TRADEMARK VIOLATION WARNING: “Q3 2017 EPS Estimates for Five Prime Therapeutics, Inc. Cut by Analyst (FPRX)” was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://transcriptdaily.com/2017/08/13/q3-2017-eps-estimates-for-five-prime-therapeutics-inc-cut-by-analyst-fprx.html.

Shares of Five Prime Therapeutics (NASDAQ FPRX) opened at 27.83 on Friday. The stock has a 50 day moving average of $29.46 and a 200-day moving average of $34.75. The stock’s market cap is $778.82 million. Five Prime Therapeutics has a 52 week low of $25.97 and a 52 week high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by $0.43. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The company had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. During the same period in the prior year, the firm earned ($0.49) EPS. Five Prime Therapeutics’s quarterly revenue was down 16.1% on a year-over-year basis.

A number of institutional investors have recently made changes to their positions in FPRX. Creative Planning increased its position in shares of Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after buying an additional 54 shares in the last quarter. Laurion Capital Management LP purchased a new position in shares of Five Prime Therapeutics during the first quarter worth approximately $210,000. Rockefeller Financial Services Inc. purchased a new position in shares of Five Prime Therapeutics during the second quarter worth approximately $210,000. BlueCrest Capital Management Ltd purchased a new position in shares of Five Prime Therapeutics during the first quarter worth approximately $254,000. Finally, Arxis Securities LLC purchased a new position in shares of Five Prime Therapeutics during the first quarter worth approximately $267,000. Institutional investors and hedge funds own 85.10% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply